[Endometrial hyperplasia--diagnosis and treatment].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Tropé CG;Tropé CG; Marth C; Scheistrøen M; Abeler VM
  • Source:
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke [Tidsskr Nor Laegeforen] 1999 May 30; Vol. 119 (14), pp. 2030-4.
  • Publication Type:
    English Abstract; Journal Article; Review
  • Language:
    Norwegian
  • Additional Information
    • Transliterated Title:
      Endometriehyperplasi--diagnose og behandling.
    • Source:
      Publisher: Norske Laegeforening Country of Publication: Norway NLM ID: 0413423 Publication Model: Print Cited Medium: Print ISSN: 0029-2001 (Print) Linking ISSN: 00292001 NLM ISO Abbreviation: Tidsskr Nor Laegeforen Subsets: MEDLINE
    • Publication Information:
      Publication: Oslo : Norske Laegeforening
      Original Publication: Chistiania : Alb. Cammermeyer, 1880-
    • Subject Terms:
      Endometrial Hyperplasia*/classification ; Endometrial Hyperplasia*/diagnosis ; Endometrial Hyperplasia*/pathology ; Endometrial Hyperplasia*/therapy; Adult ; Aged ; Female ; Guidelines as Topic ; Humans ; Middle Aged ; Risk Factors ; World Health Organization
    • Abstract:
      The International Society of Gynecological Pathologists recently agreed on a classification of endometrial hyperplasia into two main groups; hyperplasias with and without atypia. The lesions were further subdivided into simple and complex hyperplasia. These guidelines were subsequently adopted by the World Health Organization. The disease is a result of oestrogen/gestagen imbalance with oestrogen overexpression. The most important prognostic factor is cellular atypia. Progress to invasive cancer is seen in about 20% of the patients with atypical hyperplasia, and most frequently occurs in postmenopausal women. The treatment of endometrial hyperplasia depends on histologic type, patients' age and whether the hyperplasia is a result of endogenous or exogenous oestrogen overexpression. The risk for progression to invasive cancer is minimal in oestrogen treated patients with simple or complex hyperplasia without atypia. Women under 40 years of age in this group can safely be treated with gestagens. In postmenopausal women with simple or complex hyperplasia with atypia, the recommended treatment is surgery including removal of the uterus and the ovaries.
    • Number of References:
      51
    • Comments:
      Comment in: Tidsskr Nor Laegeforen. 1999 Aug 10;119(18):2693-4. (PMID: 10479989)
    • Publication Date:
      Date Created: 19990708 Date Completed: 19990713 Latest Revision: 20080716
    • Publication Date:
      20240829
    • Accession Number:
      10394278